Global precision cancer treatments market surged by $211 billion due to platform-based approaches; FDA oncology approvals show industry shift.
GT Biopharma, Inc. announced in Vancouver, BC on December 11, 2025, that November saw a surge in FDA oncology approvals, indicating a trend towards platform-based precision therapies instead of broad-spectrum treatments. This shift highlights the global focus on anticancer advancements.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments